Acceleron Pharma Total Liabilities

Acceleron Pharma (XLRN) currently reports a total liabilities of $70M as of September 2021. That compares with $53M in the prior-year period — up 32.4% year over year. Use the charts on this page to explore Acceleron Pharma's total liabilities history and peer comparisons.

Acceleron Pharma's total liabilities increased from $53M to $70M — a 32.4% year-over-year increase (period ending September 2021). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Acceleron Pharma reported $70M in total liabilities as of September 2021. That compares with $53M in the prior-year period — up 32.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $70M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Acceleron Pharma, and consider following XLRN for alerts when major investors trade the stock.

Acceleron Pharma is classified in the Healthcare sector. On total liabilities, it currently shows $70M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing XLRN with unrelated industries.